Skip to main content

ERRATUM article

Front. Pharmacol., 31 March 2021
Sec. Experimental Pharmacology and Drug Discovery
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.672778

Erratum: Discovery and Preclinical Development of Orally Active Small Molecules That Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism

This article is an erratum on:

  1. Discovery and Preclinical Development of Orally Active Small Molecules that Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An erratum on

Discovery and Preclinical Development of Orally Active Small Molecules That Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism

by Nataraja S., Yu H., Guner J. and Palmer S. (2021). Front. Pharmacol. 11:602593. doi:10.3389/fphar.2020.602593

Due to a production error, Supplementary Figures S1, S2 were missing, and Supplementary Figure S3 was used in the article instead of Figure 3. Furthermore, the in-text citation for the tables were incorrect. The in-text citations were updated, the corrected Figure 3 appears below, and the supplementary file has been updated.

FIGURE 3
www.frontiersin.org

FIGURE 3. Dose response of hCG, TOP5300 and TOP5668 in rat Leydig cells. Compounds were incubated for 3 h in Leydig cells and testosterone in supernatant measured. Data mean + SD n = 3 (for TOP5668, n = 1), Triplicate determination in each experiment.

The publisher apologizes for this mistake. The original version of this article has been updated.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.602593/full#supplementary-material.

Keywords: follicle stimulating hormone, oral FSHR allosteric agonist, g-protein coupled receptor, infertility treatment, follicular maturation, oocyte viability

Citation: Frontiers Production Office (2021) Erratum: Discovery and Preclinical Development of Orally Active Small Molecules That Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism. Front. Pharmacol. 12:672778. doi: 10.3389/fphar.2020.602593

Received: 26 February 2021; Accepted: 26 February 2021;
Published: 31 March 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.